Nemaura Medical Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NMRD research report →
Price Chart
About the company
Nemaura Medical Inc. is a medical technology company dedicated to inventing, developing, and bringing to market diagnostic medical devices. Its flagship product, sugarBEAT, is an innovative, non-invasive continuous glucose monitoring (CGM) system.
- CEO
- Dewan Fazlul Hoque Chowdhury
- IPO
- 2018
- Employees
- 38
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on NMRD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.04K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.05
- P/B
- -0.00
- EV/EBITDA
- -1.36
- Div Yield
- 0.00%
- Gross Margin
- -1916.30%
- Op Margin
- -12454.23%
- Net Margin
- -18358.00%
- ROE
- 249.27%
- ROIC
- -103.87%
Latest fiscal year · YoY change
- Revenue
- $77.04K-84.7%
- Gross Profit
- $-1,476,392-1025.0%
- Op Income
- $-9,595,234
- Net Income
- $-14,143,735-1.9%
- EPS
- $-0.57+3.4%
- OCF Growth
- -29.9%
- FCF Growth
- -20.5%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.92
- RSI (14)
- 51
- Avg Volume
- 1.08K
No earnings-call transcripts are available for NMRD yet.
- Free Float
- 42.8%
- Shares Outstanding
- 40.35M
- Float Shares
- 17.26M
of shares held by institutions
18 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for NMRD, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Dianne FeinsteinSenate · CA | Sell | Jan 10, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 5, 24 | Ghadar-Ghadr Arash | buy | 100,000 |
| Jan 5, 22 | Ghadar-Ghadr Arash | other | 0 |
| Jan 28, 22 | Natha Salim | other | 8,000 |
| Jan 28, 22 | Moore Thomas Peter | other | 8,000 |
| Jan 31, 22 | Mclarney Justin James | other | 22,293 |
| Jan 28, 22 | Johnson Timothy Christopher | other | 8,000 |
| Jan 28, 22 | Chowdhury Dewan Fazlul Hoque | other | 8,000 |
| Jan 28, 22 | Timol Bashir | other | 8,000 |
| Aug 3, 17 | Moore Thomas Peter | other | 0 |
| Jul 17, 17 | Johnson Timothy Christopher | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NMRD coverage
Recent articles, reports, and earnings notes.
No research on NMRD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NMRD report →Reviewing InfuSystem (NYSE:INFU) and Nemaura Medical (OTCMKTS:NMRD)
defenseworld.net · Mar 9
Important Update on Listing Status and Strategic Direction
globenewswire.com · Jan 3
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision
globenewswire.com · Dec 13
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth
globenewswire.com · Nov 21
Nemaura (NMRD) to Expand in UK With Metabolic Health Program
zacks.com · Nov 17
Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
globenewswire.com · Nov 14
Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update
globenewswire.com · Nov 13
Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs.
globenewswire.com · Sep 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.